rhyncophylline and Atherosclerosis

rhyncophylline has been researched along with Atherosclerosis* in 1 studies

Other Studies

1 other study(ies) available for rhyncophylline and Atherosclerosis

ArticleYear
Isorhynchophylline inhibits inflammatory responses in endothelial cells and macrophages through the NF-κB/NLRP3 signaling pathway.
    BMC complementary medicine and therapies, 2023, Mar-11, Volume: 23, Issue:1

    Atherosclerosis is a chronic inflammatory disease of arterial wall, which is closely related to inflammatory reaction. In this study, the anti-inflammatory effect of isorhynchophylline was studied by NF- κB / NLRP3 pathway.. (1) ApoE. (1) the expression of NLRP3, NF- κB, IL-18 and Caspase-1 in aorta of model group was higher than that of control group, and plaque formation was obvious. (2) the expressions of NLRP3, NF- κB, IL-18 and Caspase-1 in HUVECs and RAW264.7 model groups were higher than those in control group, while isorhynchophylline decreased their expression and enhanced cell migration ability.. Isorhynchophylline can reduce the inflammatory reaction induced by lipopolysaccharide and promote the ability of cell migration.

    Topics: Animals; Atherosclerosis; Caspases; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Interleukin-18; Lipopolysaccharides; Macrophages; Mice; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction

2023